Specialty Drug Market Access Reality Check: Ten payer pressures to act on now
Specialty Drug Market Access Reality Check: Ten payer pressures to act on now
Insight

Specialty Drug Market Access Reality Check

Ten payer pressures to act on now

Debates about market access in the specialty drug realm are heating up. This is especially true for products targeting indications with exceedingly high levels of medical need. These are the diseases we call “breakthrough innovation areas” since rapid advancements in the standard of care are either occurring or planned. Major breakthrough innovation drugs are being introduced to treat cancer, autoimmune diseases, rare genetic disorders, Alzheimer’s, and pandemic infectious diseases. Approaches to product development, marketing and pricing are already unique in these areas, and the landscape is still evolving.

Specialty Drug Market Access Reality Check
Ten payer pressures to act on now

Related content


KPMG Healthcare & Life Sciences Institute

Register to receive timely insights